This article is
- freely available
Radiolabelling of Antigen and Liposomes for Vaccine Biodistribution Studies
School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK
* Author to whom correspondence should be addressed.
Received: 19 March 2010; in revised form: 29 March 2010 / Accepted: 30 March 2010 / Published: 31 March 2010
Abstract: A relatively simple and effective method to follow the movement of pharmaceutical preparations such as vaccines in biodistribution studies is to radiolabel the components. Whilst single radiolabelling is common practice, in vaccine systems containing adjuvants the ability to follow both the adjuvant and the antigen is favourable. To this end, we have devised a dual-radiolabelling method whereby the adjuvant (liposomes) is labelled with 3H and the antigen (a subunit protein) with 125I. This model is stable and reproducible; we have shown release of the radiolabels to be negligible over periods of up to 1 week in foetal calf serum at 37 ºC. In this paper we describe the techniques which enable the radiolabelling of various components, assessing stability and processing of samples which all for their application in biodistribution studies. Furthermore we provide examples derived from our studies using this model in tuberculosis vaccine biodistribution studies.
Keywords: liposomes; vaccines; radiolabelling; pharmacokinetics; biodistribution
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Henriksen-Lacey, M.; Bramwell, V.; Perrie, Y. Radiolabelling of Antigen and Liposomes for Vaccine Biodistribution Studies. Pharmaceutics 2010, 2, 91-104.
Henriksen-Lacey M, Bramwell V, Perrie Y. Radiolabelling of Antigen and Liposomes for Vaccine Biodistribution Studies. Pharmaceutics. 2010; 2(2):91-104.
Henriksen-Lacey, Malou; Bramwell, Vincent; Perrie, Yvonne. 2010. "Radiolabelling of Antigen and Liposomes for Vaccine Biodistribution Studies." Pharmaceutics 2, no. 2: 91-104.